Skip to main content

Abciximab Pregnancy and Breastfeeding Warnings

Brand names: ReoPro

Abciximab Pregnancy Warnings

Abciximab has been assigned to pregnancy category C by the FDA. Animal reproduction studies have not been conducted with abciximab. It is also not known whether abciximab can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. Abciximab should only be given during pregnancy when benefit outweighs risk.

See references

Abciximab Breastfeeding Warnings

There are no data on the excretion of abciximab into human milk. The manufacturer recommends that caution be used when administering abciximab to nursing women.

See references

See also

References for pregnancy information

  1. Product Information. ReoPro (abciximab). Lilly, Eli and Company. 2001;PROD.

References for breastfeeding information

  1. Product Information. ReoPro (abciximab). Lilly, Eli and Company. 2001;PROD.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer